Aytu BioScience (AYTU) Price & Analysis

Compare

1,260 Followers

AYTU Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.95 - $2.85

Previous CloseN/A

Volume5.78K

Average Volume (3M)143.52K

Market Cap

$13.57M

Enterprise Value$14.20M

Total Cash (Recent Filing)$18.17M

Total Debt (Recent Filing)$1.86M

Price to Earnings (P/E)―

Beta1.74

Next Earnings

Sep 25, 2025

EPS Estimate

-0.03

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.20

Shares Outstanding6,170,246

10 Day Avg. Volume104,629

30 Day Avg. Volume143,522

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap1.05

Enterprise Value/Revenue0.21

Enterprise Value/Gross Profit0.30

Enterprise Value/Ebitda4.49

Forecast

1Y Price Target

$9.67

Price Target Upside349.77% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Clinical PerformanceEXXUA has demonstrated significant improvement in depression symptoms in clinical trials involving more than 5,000 patients, with side effects comparable to placebo.

Financial PerformanceAytu reported F3Q25 results with total revenue of $18.5M, exceeding the estimate of $13.7M.

Market OpportunityEXXUA is targeting the $22 billion U.S. prescription MDD market and aims to become an important treatment option for the 21 million Americans affected by MDD.

Bears Say

Management StrategyManagement is evaluating business development and acquisition opportunities to grow beyond the ADHD franchise.

Price Target AdjustmentThe analyst has updated estimates and raised the 12-month price target to $9 for AYTU.

Aytu BioScience News

Aytu BioPharma management to meet with Maxim

Institutional Group Dinner Meeting with Management to be held in Stamford, CT on July 17 hosted by Maxim....

1M ago

AYTU

Aytu, Hasbro, Hyatt, Gen Digital, Carrier: Trending by Analysts

Analysts are intrested in these 5 stocks: ( ($AYTU) ), ( ($HAS) ), ( ($H) ), ( ($GEN)...

2M ago

GEN

Aytu BioPharma initiated with a Buy at Lake Street

Lake Street initiated coverage of Aytu BioPharma (AYTU) with a Buy rating and $8 price target The firm...

2M ago

AYTU

Aytu BioPharma initiated with a Buy at Ascendiant

Ascendiant initiated coverage of Aytu BioPharma (AYTU) with a Buy rating and $12 price target Aytu recently announced...

2M ago

AYTU

Aytu BioPharma appoints Gerwin Westfield as SVP, scientific affairs

Aytu BioPharma (AYTU) announced the appointment of Dr. Gerwin Westfield, PhD as Senior Vice President of Scientific Affairs,...

2M ago

AYTU

Aytu BioScience Expands Lending Agreement for EXXUA Launch

An announcement from Aytu BioScience ( ($AYTU) ) is now available. On June 20, 2025, Aytu BioPharma, Inc....

2M ago

AYTU

Aytu BioPharma expands, extends lending agreement with Eclipse

Aytu BioPharma (AYTU) expanded and extended its lending agreement with Eclipse Business Capital, providing added working capital flexibility...

2M ago

AYTU

Aytu BioPharma’s Strategic Acquisition of EXXUA Drives Buy Rating and Raises Price Target

In a report released yesterday, Naz Rahman from Maxim Group reiterated a Buy rating on Aytu BioScience (AYTU...

2M ago

AYTU

Aytu BioPharma Closes $16.6M Stock Offering for EXXUA

Aytu BioScience ( ($AYTU) ) has provided an announcement. On June 9, 2025, Aytu BioPharma announced the closing...

2M ago

AYTU

Aytu BioScience Signs Exclusive Agreement for EXXUA

Aytu BioScience ( ($AYTU) ) has shared an update. On June 5, 2025, Aytu BioPharma entered an Exclusive...

3M ago

AYTU

Aytu BioPharma Announces $12.9M Public Offering

The latest announcement is out from Aytu BioScience ( ($AYTU) ). On June 5, 2025, Aytu BioPharma announced...

3M ago

AYTU

Aytu BioPharma 9.6M share Secondary priced at $1.50

The deal size was increased to 9.6M shares of common stock from 6.7M shares of common stock. Lake...

3M ago

AYTU

Aytu BioPharma enters exclusive agreement with Fabre-Kramer Pharmaceuticals

Aytu BioPharma (AYTU) announced the signing of an exclusive agreement to commercialize EXXUAextended-release tablets in the United States....

3M ago

AYTU

Aytu BioPharma prices 9.6M shares at $1.50 in upsized public offering

Aytu BioPharma (AYTU) announced the pricing of an upsized public offering of 9,600,000 shares of common stock at...

3M ago

AYTU

AYTU FAQ

What was Aytu BioScience Inc’s price range in the past 12 months?

Aytu BioScience Inc lowest stock price was $0.95 and its highest was $2.85 in the past 12 months.

What is Aytu BioScience Inc’s market cap?

Aytu BioScience Inc’s market cap is $13.57M.

When is Aytu BioScience Inc’s upcoming earnings report date?

Aytu BioScience Inc’s upcoming earnings report date is Sep 25, 2025 which is in 35 days.

How were Aytu BioScience Inc’s earnings last quarter?

Aytu BioScience Inc released its earnings results on May 14, 2025. The company reported $0.2 earnings per share for the quarter, beating the consensus estimate of -$0.17 by $0.37.

Is Aytu BioScience Inc overvalued?

According to Wall Street analysts Aytu BioScience Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Aytu BioScience Inc pay dividends?

Aytu BioScience Inc does not currently pay dividends.

What is Aytu BioScience Inc’s EPS estimate?

Aytu BioScience Inc’s EPS estimate is -0.03.

How many shares outstanding does Aytu BioScience Inc have?

Aytu BioScience Inc has 6,170,246 shares outstanding.

What happened to Aytu BioScience Inc’s price movement after its last earnings report?

Aytu BioScience Inc reported an EPS of $0.2 in its last earnings report, beating expectations of -$0.17. Following the earnings report the stock price went up 91.852%.

Which hedge fund is a major shareholder of Aytu BioScience Inc?

Currently, no hedge funds are holding shares in AYTU

Company Description

Aytu BioScience Inc

Aytu BioScience, Inc. is a specialty pharmaceutical company focused on commercializing novel products in the fields of urology and men's health. The company's core products include prescription and over-the-counter options designed to address unmet medical needs in these therapeutic areas. Aytu BioScience aims to improve patient outcomes through innovative solutions that enhance standard treatment protocols.

Aytu BioScience (AYTU) Earnings & Revenues

Historic Earnings Reports

AYTU Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects a strong quarter for Aytu BioPharma with significant revenue growth, operational efficiencies, and improved financial metrics. The company's strategic initiatives are yielding positive results, although there are some challenges related to gross margin and potential macroeconomic impacts. Overall, the sentiment is positive, driven by the company's financial achievements and growth trajectory.View all AYTU earnings summaries

AYTU Stock 12 Month Forecast

Average Price Target

$9.67

▲(349.77% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","13":"$13","3.25":"$3.25","6.5":"$6.5","9.75":"$9.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.25,6.5,9.75,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.26,3.009230769230769,3.758461538461538,4.507692307692308,5.256923076923076,6.006153846153846,6.7553846153846155,7.504615384615384,8.253846153846155,9.003076923076923,9.752307692307692,10.50153846153846,11.250769230769231,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.26,2.83,3.4,3.9699999999999998,4.54,5.11,5.68,6.25,6.82,7.390000000000001,7.960000000000001,8.530000000000001,9.100000000000001,{"y":9.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.26,2.7015384615384614,3.143076923076923,3.5846153846153843,4.026153846153846,4.467692307692308,4.909230769230769,5.350769230769231,5.792307692307692,6.233846153846153,6.6753846153846155,7.116923076923077,7.558461538461538,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.89,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.15,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.61,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.5,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.35,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.94,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.63,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.7,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.66,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.16,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.34,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.78,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.26,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >